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Abstract: Background: In January 2017, the Dutch cervical cancer screening programme transitioned from
cytomorphological to primary high-risk HPV (hrHPV) DNA screening, including the introduction of self-sampling, for
women aged between 30 and 60 years. The Netherlands was the first country to switch to hrHPV screening at the
national level. We investigated the health impact of this transition by comparing performance indicators from the
new hrHPV-based programme with the previous cytology-based programme.
Methods: We obtained data from the Dutch nationwide network and registry of histo- and cytopathology (PALGA) for
454,573 women eligible for screening in 2017 who participated in the hrHPV-based programme between 1 January
2017 and 30 June 2018 (maximum follow-up of almost 21months) and for 483,146 women eligible for screening in
2015 who participated in the cytology-based programme between 1 January 2015 and 31 March 2016 (maximum
follow-up of 40months). We compared indicators of participation (participation rate), referral (screen positivity; referral
rate) and detection (cervical intraepithelial neoplasia (CIN) detection; number of referrals per detected CIN lesion).
Results: Participation in the hrHPV-based programme was significantly lower than that in the cytology-based
programme (61% vs 64%). Screen positivity and direct referral rates were significantly higher in the hrHPV-based
programme (positivity rate: 5% vs 9%; referral rate: 1% vs 3%). CIN2+ detection increased from 11 to 14 per 1000
women screened. Overall, approximately 2.2 times more clinical irrelevant findings (i.e. ≤CIN1) were found in the
hrHPV-based programme, compared with approximately 1·3 times more clinically relevant findings (i.e. CIN2+); this
difference was mostly due to a national policy change recommending colposcopy, rather than observation, of hrHPV-
positive, ASC-US/LSIL results in the hrHPV-based programme.
Conclusions: This is the first time that comprehensive results of nationwide implementation of hrHPV-based screening
have been reported using high-quality data with a long follow-up. We have shown that both benefits and potential
harms are higher in one screening round of a well-implemented hrHPV-based screening programme than in an
established cytology-based programme. Lower participation in the new hrHPV programme may be due to factors such
as invitation policy changes and the phased roll-out of the new programme. Our findings add further to evidence from
trials and modelling studies on the effectiveness of hrHPV-based screening.
Keywords: Cervical cancer screening, hrHPV screening, Population-based screening, Cancer screening programmes
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: c.aitken@erasmusmc.nl
1Department of Public Health, Erasmus MC University Medical Center, Dr.
Molewaterplein 40, 3015 CN Rotterdam, the Netherlands
Full list of author information is available at the end of the article
Aitken et al. BMC Medicine          (2019) 17:228 
https://doi.org/10.1186/s12916-019-1460-0
Background
Primary high-risk HPV (hrHPV) DNA screening, evalu-
ated in clinical trials, has been shown to be more effect-
ive and cost-effective than cytology screening for the
detection of pre-malignant and malignant cervical le-
sions [1, 2]. Following advice from the Dutch Health
Council [3] and a feasibility study by the Dutch National
Institute for Public Health and the Environment (RIVM)
[4], primary hrHPV screening replaced cytology screening
in the Dutch national cervical cancer screening programme
in January 2017. Each of the five regional screening organi-
sations implemented hrHPV-based screening sequentially
during the first quarter of 2017, and by April 2017, the na-
tional implementation was complete. Women can choose
either to have a cervical smear taken by their general prac-
titioner (GP) or to use a self-sampling kit [5]. Laboratory
testing of screening programme samples is performed in
five dedicated screening laboratories.
As part of the initial feasibility study, modelling ana-
lysis was conducted assessing the costs and effects of
implementing primary hrHPV-based screening in the
Netherlands [4]. Recent modelling estimated that nation-
wide implementation of primary hrHPV-based screening
was expected to reduce cervical cancer diagnoses by 13%
and related deaths by 15% compared with cytology-
based screening, while also reducing overall programme
costs [6].
The success of a screening programme depends on the
implementation of well-defined protocols and guidelines
[7]. Screening programmes should be regularly moni-
tored using high-quality data for quality assurance, to
evaluate effectiveness and to identify potential harms [8].
Although results from the implementation of primary
hrHPV screening in Italy and Turkey have been pub-
lished [9, 10], these data lack robust results on detection
of cervical intraepithelial neoplasia (CIN) lesions and
do not compare the performance of hrHPV screening
with cytology-based screening. Results from the Italian
programme were also limited to a number of regions.
Comprehensive results from the implementation of a
nationwide hrHPV screening programme have yet to be
published.
Data from the Dutch nationwide network and registry
of histo- and cytopathology (PALGA) has enabled regu-
lar, high-quality monitoring of organised cervical cancer
screening in the Netherlands for many years. This
comprehensive dataset has national coverage [11],
enabling us to assess the impact of cervical cancer
screening programme policies on a national level. In
order to evaluate the performance of the new primary
hrHPV-based screening programme, we aimed to com-
pare outcomes of the first year of the new programme
with outcomes of the previous cytology-based cervical
cancer screening programme.
Methods
The cytology-based Dutch cervical screening programme
Until the end of 2016, the Dutch cervical cancer screen-
ing programme used cytology as the primary screening
test. Women were invited to make an appointment for
screening with their GP every 5 years from ages 30 to
60. Women could choose to opt out of screening either
temporarily (in the case of pregnancy, illness or other
short-term reasons) or indefinitely (in the case of hyster-
ectomy or non-medical reasons such as conscientious
objection).
There were various referral pathways in the cytology-
based programme, depending on the result of primary
cytology screening (Fig. 1a). Direct referrals for colpos-
copy were given to women with high-grade cervical
cytological abnormalities (high-grade squamous intrae-
pithelial lesion (HSIL)) at primary screening. If women
had low-grade cervical cytological abnormalities (atypical
squamous cells of undetermined significance (ASC-US)
or low-grade squamous intraepithelial lesion (LSIL)) at
primary screening, they were advised to make an ap-
pointment with their GP after 6 months for a follow-up
smear. For women advised to have a follow-up cytology
at 6 months, hrHPV triage was used in some cases,
depending on the policy of the laboratory performing
the test. Referral advice was given to women at the 6-
month screening who had the following result: (a) ASC-
US or higher (when no hrHPV triage was performed) or,
in the case of hrHPV triage, (b) ASC-US/LSIL and
hrHPV-positive or (c) HSIL. Further repeat testing at 18
months was advised for women with cytology negative
for intraepithelial lesion or malignancy (NILM) when no
hrHPV triage was used or for NILM, hrHPV-positive
results or ASC-US/LSIL, hrHPV-negative results. When
hrHPV triage testing at 6 months was used, women were
referred back for routine screening if they were hrHPV-
negative and cytology-negative. All women with ASC-
US+ cytology at 18 months were referred.
The hrHPV-based Dutch cervical screening programme
Primary hrHPV screening was implemented in the
Netherlands on 1 January 2017 (Fig. 1b), replacing the
cytology-based programme. Women are invited to par-
ticipate by their regional screening organisation every
5 years between the ages of 30 and 60, with some excep-
tions based on hrHPV positivity in the previous screen-
ing round; women with a negative hrHPV test result at
age 40 or 50 are invited for screening after 10 years
instead of 5 and women who test hrHPV-positive at age
60 are invited for final screening at age 65. Women who
do not wish to have a cervical sample taken at their GP
can request a self-sampling kit. If requested at primary
invitation, women were sent the self-sampling kit ap-
proximately 4 months after the initial invitation letter.
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Fig. 1 a Screening protocol of the cytology-based screening programme. b Screening protocol of the HPV-based screening programme. NILM
negative for intraepithelial lesion or malignancy, ASC-US atypical squamous cells of undetermined significance, LSIL low-grade squamous
intraepithelial lesion, HSIL high-grade squamous intraepithelial lesion
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Non-responders received a reminder letter 4 months
after the initial invitation, which also contained informa-
tion about how to request the self-sampling kit. Women
who requested the self-sampling kit after this reminder
received it immediately. Reflex cytology was immediately
performed on hrHPV-positive GP-collected samples. As
cytology on self-sampled cervicovaginal material is unre-
liable [12, 13], women with an hrHPV-positive result on
self-sampling were invited to have a cytological smear
taken by their GP.
The referral algorithm in the hrHPV-based programme
was simplified. HrHPV-positive women with cytological
abnormalities (i.e. ASC-US or worse) were referred for
colposcopy, while hrHPV-positive women with normal
cytology were invited for repeat cytology testing after
6 months.
Organisational and policy differences between the two
programmes
In the Netherlands, there are five regional screening or-
ganisations responsible for the implementation of the
screening programme. With the change from cytology-
based to hrHPV-based screening, the policy for inviting
women was changed, with the regional screening organi-
sations sending all invitations in a standard manner;
women were all invited after their birthday in the year
they were eligible for invitation. In the cytology-based
programme, invitations were sent by the regional screen-
ing organisation, GP practices or using a combined ap-
proach. The timing of the invitation also varied depending
on which organisation sent the invitation; some invitations
were sent at the start of the year that women would be-
come eligible to participate, and some were sent after the
women’s birthdate. The number of laboratories respon-
sible for analysing primary screens from the programme
was reduced from approximately 40 in the cytology-based
programme to five in the hrHPV-based programme (one
per region).
hrHPV test in the new programme
Clinician-collected samples were collected in 20 ml
ThinPrep medium (Hologic, Marlborough, MA, USA),
transported and stored at room temperature until proc-
essed in the laboratory. The Evalyn® Brush (Rovers Medical
Devices, Oss, the Netherlands) was used for self-sampling.
The self-collected brushes were sent to the laboratories by
regular mail. The brush of the self-sampling device was
transferred into 20ml of ThinPrep medium prior to
hrHPV testing. All laboratories used the cobas® 4800 HPV
test (Roche Diagnostics, Alameda, CA, USA) to test the
clinician-collected and self-samples. The cobas® 4800 HPV
test is a CE in vitro diagnostic (IVD) certified kit (for
clinician-collected cervical scraps only) for use in combin-
ation with the cobas® 4800 system for nucleic acid
extraction, PCR setup, real-time PCR amplification and
result analysis. As part of the assay procedure, each sample
was also tested for the presence of human cells by amplifi-
cation of the human beta-globin gene. The clinical per-
formance of the cobas® 4800 system has been validated
using Dutch samples [14], and the Evalyn® Brush was com-
pared with lavage self-sampling in a Dutch population and
found to have equivalent performance [15]. All tests used
in the hrHPV-based programme were selected through a
tendering process.
Study design and data source
This study is a longitudinal, retrospective population-
based cohort study. We obtained results of primary
screening tests and any associated follow-up from the
Dutch nationwide network and registry of histo- and
cytopathology (PALGA) for two cohorts. The cytology
cohort consisted of women who participated in the
cytology-based screening programme between 1 January
2015 and 31 March 2016 (maximum follow-up of 40
months). The hrHPV cohort consisted of women who
participated between 1 January 2017 and 30 June 2018
in the hrHPV screening programme (maximum follow-
up of almost 21 months). An inclusion period of 18
months was used for the hrHPV cohort to compensate
for the phased implementation of the new programme
(see Additional file 1).
All pathology laboratories in the Netherlands are
linked to PALGA [11]. Identification of women is based
on their birthdate and up to the first eight letters of their
surname (maiden name is used for married women) and
allows linkage of tests belonging to the same woman,
enabling individual screening histories to be followed.
For all primary and follow-up tests, the corresponding
advice codes were analysed. Age was defined as the
woman’s age at the time of the primary screening
test, classified into 5-year age groups. Given differ-
ences in invitation policies between the two pro-
grammes, slightly different age ranges have been used
for the hrHPV cohort and the cytology cohort (see
Additional file 1).
Data analysis
To compare the performance of the hrHPV-based
screening programme with the cytology-based screening
programme, we calculated indicators in three categories:
participation (participation rate), referral (screen positivity
rate, positive cytology amongst screen-positive women,
referral rate from primary screening (direct referral), refer-
ral rate from follow-up smear (indirect referral) and total
referral rate (direct and indirect referrals combined)) and
detection (findings after referral per 1000 screened
women, number of positive screen test results/number of
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referrals for colposcopy per detected CIN2+ or CIN3+
lesion).
The participation rate was defined by the number of
primary screening tests divided by the number of women
eligible for screening. The number of eligible women was
estimated from the number of women in the Dutch popu-
lation who would reach screening age in 2015 or 2017 (i.e.
aged 29, 34, etc.) on 1 January 2015 for the cytology
cohort and on 1 January 2017 for the hrHPV cohort. This
data was obtained from Statistics Netherlands [16] and
adjusted for the risk of having their cervix removed by
hysterectomy [17].
Referrals were identified based on advice codes re-
corded in PALGA and could be direct or indirect (see
Additional file 1). Overdiagnosis and false positive
screening results are recognised harms of screening [18].
Screen positivity and referrals can lead to psychological
distress [19, 20], and colposcopy itself can result in phys-
ical symptoms [21]. As such, we considered screen posi-
tivity and referral to be proxies for potential harms. To
estimate the harms-benefits ratio of screening, we calcu-
lated the number of screen positives and number of
referrals per detected CIN2+ and CIN3+ case. Detailed
information about data definitions can be found in
Additional file 1.
All analyses were performed using IBM SPSS Statistics
24. Chi-squared tests were performed to compare differ-
ences between proportions. p values of 0.05 or less were
statistically significant.
Results
Participation
A total of 454,573 women eligible for screening invitation
in 2017 participated in the hrHPV-based programme
between 1 January 2017 and 30 June 2018 and 483,146
women eligible for screening invitation in 2015 partici-
pated in the cytology-based programme between 1 Janu-
ary 2015 and 31 March 2016. Women ranged in age from
29 to 61 years.
Figure 2 shows that the overall participation rate in the
hrHPV-based programme in 2017 was significantly lower
than that in the cytology-based screening programme in
2015 (64% in 2015 compared with 61% in 2017; p < 0.001).
The participation rate in the hrHPV-based programme was
lower in all age groups. The biggest difference was found in
age group 45–49 years (68% in 2015 compared with 63% in
2017; p < 0.001). Differences in participation rates were
statistically significant for all age groups (p < 0.001).
The percentage of inadequate cytology smears re-
corded at primary screening as a proportion of all pri-
mary screening reduced from 1.6% in 2015 to 0.1% in
2017 (p < 0.001).
Of all women participating in the hrHPV-based
programme, 8% used the self-sampling kit (i.e. 36,295
self-sampled compared with 418,278 clinician-collected)
(Fig. 3).
Referral
Figure 4 shows that the proportion of women with a
positive screen test was significantly higher in the
hrHPV-based programme than in the cytology-based
programme (increased from 5% in 2015 to 9% in 2017;
p < 0.001). Related to this, we found that the proportion
of women referred to the gynaecologist also significantly
increased (from 1% in the cytology-based programme to
3% in the hrHPV-based programme; p < 0.001). The in-
creases in positive screen tests and in the referral rate
were largest in women aged 30–34 years, where the pro-
portion of positive screen tests increased from 9% in the
cytology-based programme to 21% in the hrHPV-based
programme (p < 0.001) and the referral rate increased
from 3% to 8% (p < 0.001).
In the hrHPV-based programme, we found a signifi-
cantly higher hrHPV positivity rate in clinician-collected
than in self-collected samples (9.2% vs 7.6%; p < 0.001).
In addition, amongst hrHPV-positive women, more
women had a cytological abnormality after self-sampling
than clinician-collected sampling (37.2% vs 32.2%;
p < 0.001) (Fig. 3).
Detection
Figure 5 shows, per 1000 women screened, the total
number of referrals (both direct and indirect) to the
gynaecologist and the number of CIN2+ lesions detected
after referral. The number of referrals increased from 20
to 39 per 1000 women screened, and the CIN2+ detec-
tion rate increased from 11 to 14 per 1000 women
screened (p < 0.001). Overall, the referral rate doubled
and the CIN2+ detection rate increased by 34% (p <
0.001). For the youngest age group, the referral rate
increased by 92% (p < 0.001) and the CIN2+ detection
rate by 30% (p < 0.001).
Cytology or histology was performed in 77% of women
directly referred to the gynaecologist in the hrHPV-
based programme (Fig. 3). In the remaining 23%, only
colposcopy was performed after referral or women were
lost to follow-up. In the case of indirect referrals, in
64.5% of clinician-collected or 56.0% of self-sampling
(p = 0.974), cytology or histology was performed. The
CIN2+ detection rate after cytology or histology varied
across the four different groups in the hrHPV-based
programme: from 35.7% in indirect referred women after
a clinician collected sample to 57.1% in direct referred
women after self-sampling (Fig. 3).
Table 1 shows the different findings after direct and
indirect referrals for the hrHPV-based and cytology-
based programmes. We found that in the hrHPV-based
programme after referral, approximately 2.2 times more
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clinically irrelevant findings were found (i.e. ‘cytology
only’, ‘no dysplasia’ or CIN1), compared with approxi-
mately 1.3 times more clinically relevant findings (i.e.
CIN2, CIN3 and cancer).
Harms versus benefits
Table 2 shows the number of positive screen tests and
number of referrals (i.e. ‘harms’) per CIN2+ and CIN3+
lesion detected (i.e. ‘benefits’) in one screening round,
for both the hrHPV-based and cytology-based screening
programmes. We found that in the new programme, the
harms per benefit increased by approximately 45% in
one screening round for CIN2+ lesions and by 51% for
CIN3+ lesions. For example, to detect one CIN3+ lesion
in the cytology-based programme, 3.0 women were re-
ferred, compared to 4.6 in the hrHPV-based programme.
This difference was mostly due to the increase in referrals
of hrHPV-positive screens with ASC-US/LSIL cytology in
the hrHPV-based programme, which stemmed from a
national policy change to refer, rather than observe,
hrHPV-positive screens with ASC-US/LSIL results.
Discussion
Main findings
The nationwide implementation of primary high-risk
HPV DNA screening in the Netherlands has been suc-
cessful, with the programme now fully implemented and
results generally as expected, apart from a lower than
anticipated participation rate. In the first year, we ob-
served a participation rate of 61%, which was lower than
observed in the previous cytology-based programme
(64%). Screen positivity was higher in the hrHPV-based
programme. The cytology programme recommended
observation of ASC-US/LSIL results, while the hrHPV-
based programme recommended colposcopic referral for
hrHPV-positive, ASC-US/LSIL results. As expected, this
Fig. 2 Participation rate in hrHPV-based screening (2017) and in cytology-based screening (2015) by age. 454,573 women participated in
the hrHPV-based screening programme, and 483,146 women participated in the cytology-based screening programme. N.B. Please refer to
Additional file 1 for a comprehensive explanation of age group criteria. *Pearson’s chi-square test significantly different between test
types (p < 0.001)
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increased both the number of colposcopic referrals and
CIN2+ lesions detected.
Factors influencing participation rates
The introduction of self-sampling had been expected to in-
crease participation, as a previous Dutch study (PROH-
TECT) found that screening non-attenders who were
offered self-sampling were more likely to be screened than
non-attenders [22]. While 8% of screened women used
self-sampling, this did not increase overall participation,
suggesting that switching is occurring. Information about
switching was not publicly reported in the 2017 official
monitoring report [23], and further research is needed into
the characteristics of women who choose for self-sampling
to provide reliable estimates of this indicator. One import-
ant difference between PROHTECT and the real-world
implementation was that women needed to opt in to self-
sampling in the screening programme. Secondly, the 4-
month waiting period for the self-sampling kit may have
delayed uptake of screening amongst women who opted
in. The self-sampling kit may be used by women who find
it more convenient than attending the GP; one of the main
reasons identified in a Dutch study for using a self-
sampling kit [24]. Finally, although self-sampling is gener-
ally acceptable to women [12], 23% of self-sampling kits re-
quested by the 2017 cohort have not yet been returned (as
of December 2018; personal communication, RIVM, 21
December 2018). Although the return of these kits would
not have a large effect on overall participation, the reasons
for not returning them should be further investigated.
Organisational factors, such as the phased roll-out of the
new programme and changes in the invitation process,
may also have resulted in lower participation. Due to the
phased roll-out of the new programme over the first quar-
ter of 2017, women had less time to take up their screening
invitations compared with the cytology-based programme,
although we still observed a lower participation rate when
calculating it based on 18months of data. If the phased im-
plementation is the cause of lower participation, we would
expect participation to increase in the coming months. In
the cytology-based programme, GP practices could invite
patients for screening, rather than women receiving an in-
vitation from the regional screening organisation. Women
who received invitations sent from GP practices were more
Fig. 3 Flowchart of participation, referral and detection within the new hrHPV-based screening programme, 2017 cohort. Pearson’s chi-square
test significantly different for hrHPV positivity, direct referral rates and follow-up smear (p < 0.001) and CIN2+ detection rates from direct referral
(p = 0.002) between clinician-collected and self-sampling. Pearson’s chi-square test not significantly different for proportions of histology or
cytology tests (from direct referral, p = 0.805; from indirect referral, p = 0.042), indirect referral rate (p = 0.974), proportions with recommendation
to await next screening invitation (p = 0.884), CIN2+ detection rates from indirect referral (p = 0.319) between clinician-collected and self-sampling.
N.B. Sum of advice after screening will not be 100% due to a proportion of screens with repeat cytology due to inadequate cytology quality or
loss to follow-up (self-sampling arm only). Cytology was assessed in 90.1% of hrHPV-positive cases in the self-sampling arm. Repeat cytology
because of inadequate cytology quality after a positive screen result was recommended in 1.3% of clinician-collected cases and 1.6% of self-
sampling cases with cytology (1.3% of self-sampling cases had other recommendations). Repeat cytology because of inadequate cytology quality
in a follow-up smear at 6 months was recommended in 1.5% of clinician-collected cases and 1.8% of self-sampling cases
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likely to participate in the cytology-based programme than
women who received invitations from screening organisa-
tions [25]. Discontinuing the involvement of GP practices
in the invitation and reminder process may have led to a
decline in participation, as invitations are now sent from
organisations that may be unfamiliar to women; this needs
further investigation.
Comparison with other studies
The hrHPV positivity rate was higher than anticipated at
9.1%, as a previous population-based Dutch study (DuSC)
found a hrHPV positivity rate of 8% amongst women of
screening age [26]. This difference may be explained by
differences in sociodemographic characteristics of women
participating in the programme overall and the women
included in DuSC. It could also be that there has been an
increase in the incidence of hrHPV infections over time.
The higher than expected hrHPV positivity rate may
explain differences between the estimated referral rate of
3.4% (based on modelling) [6] and the observed referral
rate of 3.9%.We found 48.2% CIN2+ detection in all
women with histologically confirmed diagnosis, which was
higher than the rate predicted by modelling (45%), which
may be due to differences in the assumed test characteris-
tics and the real-world performance of the hrHPV test [6].
One surprising finding was that hrHPV positivity was
lower in self-samples than in the clinician-collected sam-
ples, contrary to previous Dutch studies. One population-
based study found higher hrHPV positivity in self-samples
than in clinician-collected samples [12], and one rando-
mised non-inferiority trial (IMPROVE) found equivalent
hrHPV positivity between the two test types, although IM-
PROVE used a different clinician-collected test than is
used in the screening programme [27]. Despite this, we
Fig. 4 Screen positivity and direct referral rates by screening programme and age. Cytology-based screening results are based on the 2015
screening cohort, and hrHPV-based screening results are based on the 2017 screening cohort. Screen positivity in the hrHPV-based screening
programme is hrHPV-positive, irrespective of reflex cytology results. 454,573 women participated in the hrHPV-based screening programme, and
483,146 women participated in the cytology-based screening programme. N.B. Please refer to Additional file 1 for a comprehensive explanation
of age group criteria. *Pearson’s chi-square test significantly different for screen positivity rates between test types (p < 0.001). †Pearson’s chi-
square test significantly different for referral rates between test types (p < 0.001)
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found higher CIN2+ detection in self-sampling than in
clinician-collected sampling. This may indicate that the
self-sampling test has a higher CIN2+ specificity than the
clinician-collected test, in contrast to results from IM-
PROVE, which reported CIN2+ specificity of the self-test
was non-inferior (relative accuracy of 1.00) [27]. Further
analysis of the self-sampling kit within the screening
programme is needed, controlling for background risk and
population factors.
Triage of hrHPV-positive women
A higher CIN2+ detection rate was found in the hrHPV
programme than in the cytology-based programme. This
was expected based on the results of four large rando-
mised trials of HPV screening [1]. However, in the new
hrHPV screening programme, more referrals per screen-
ing round were needed to detect one CIN2+ lesion com-
pared with cytology-based screening, mainly due to an
increase in the number of referrals amongst women with
ASC-US/LSIL cytology. This increase potentially leads to
more harms for women, including anxiety for women
unnecessarily referred [19] or potential overtreatment of
low-grade lesions. Therefore, optimising triage to reduce
unnecessary referrals should be a priority. Different triage
strategies for hrHPV-positive screens have been proposed,
including (but not limited to) p16/Ki67 dual staining,
hrHPV genotyping, methylation, HPV E6 protein assays or
combinations of these strategies [28]. Risk-based manage-
ment could also be explored, in which risk factors (such as
a woman’s screening history) are taken into account when
triaging hrHPV-positive, ASC-US primary screens [29].
The performance of additional triage tests in the Dutch
setting as well as the feasibility of implementation, any im-
pacts on programme cost-effectiveness and the balance of
harms versus benefits of the screening programme need to
be considered prior to changing the triage algorithm. The
harms-benefits ratio of the old cytology-based programme
was considered acceptable in the Netherlands, and while in
one round of screening the hrHPV-based screening
programme had a more unfavourable balance, reducing the
Fig. 5 Total referral and CIN2+ detection rates in all screened women by screening programme and age. Cytology-based screening results are
based on the 2015 screening cohort, and hrHPV-based screening results are based on the 2017 screening cohort. 454,573 women participated in
the hrHPV-based screening programme, and 483,146 women participated in the cytology-based screening programme. Referral rates include
direct and indirect referrals. N.B. Please refer to Additional file 1 for a comprehensive explanation of age group criteria. *Pearson’s chi-square test
significantly different for referral rates between test types (p < 0.001). †Pearson’s chi-square test significantly different for CIN2+ detection rates
between test types (p < 0.001)
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number of total screening rounds in the hrHPV-based
programme (from seven to five for many women) will re-
sult in similar overall lifetime harms-benefits ratio to that of
the cytology-based programme.
International comparisons
In several countries, hrHPV-based screening has been im-
plemented, but published results are only available from
Italy and Turkey. In Italy, HPV-based screening was imple-
mented in 2012 in 19 screening programmes across ten re-
gions. The direct referral rate from the Italian programme
was comparable with the Dutch programme at 2.9% [10]. In
2014, primary HPV screening was implemented in Turkey;
however, a direct comparison of results is difficult due to a
low participation rate (36.5%) and incomplete histological
follow-up data [9]. Neither study compared hrHPV-based
screening with cytology-based screening. In general, the
quality of a cytology-based programme influences such a
comparison. In the Netherlands, the quality of the cytology-
based programme was consistently high, with low rates of
unsatisfactory smears and a high positive predictive value
for CIN2+ lesions compared with other European countries
[30]. In a country with a less highly performing cytology
programme, the incremental effects of HPV-based screening
versus cytology-based screening would be different.
Future implications for hrHPV screening in partly
vaccinated cohorts
Given the increased sensitivity of hrHPV testing for
CIN2+ lesions, detection rates are expected to be higher
in the first round, as both prevalent and incident lesions
are detected. As the programme reaches a steady state,
and fewer prevalent lesions are detected, we expect that
detection of CIN3+ lesions will decrease, as seen in the
POBASCAM trial [31]. Therefore, it will be necessary to
compare results from the first and subsequent screening
rounds. In the Netherlands, hrHPV vaccination was
offered in a catch-up programme to girls aged 13 to 16
years in 2009, meaning the first cohort of partly vacci-
nated women will be eligible for screening in 2023. This
may necessitate changes to the programme, due to an
anticipated reduction in HPV16/18 infections. Modelling
has shown that with herd immunity levels greater than
50%, a reduction in the number of screening rounds
may need to be considered to maintain programme
cost-effectiveness in the Netherlands [32]. Finally, for
full evaluation of the new screening programme, calcula-
tion of interval cancer incidence is essential to approxi-
mate the sensitivity of one screening round. Women are
at highest risk of an interval cancer diagnosis 4 to 6 years
after a negative screen [33], as the screening interval is
5 years. As such, the first opportunity for comparison of
this indicator will come 5 years after the implementation
of hrHPV-based screening.
Strengths and limitations of this study
This is the first study to report the results of the nation-
wide implementation of a hrHPV-based screening using
prospectively collected cyto- and histopathological data.
We have been able to compare this reliably with the pre-
vious cytology-based programme due to the nationwide
coverage of PALGA. The large number of screens
Table 2 Number of positive screen tests and number of referrals per detected CIN2+ or CIN3+ lesion
Cytology HPV Difference per round (%)
Positive screens
Total*
Number of positives needed to detect one CIN2+ 4.4 6.3 44
CIN3+ 7.2 10.8 50
Referrals
Total*
Number of referrals needed to detect one CIN2+ 1.9 2.7 47
CIN3+ 3.0 4.6 53
HSIL
Number of referrals needed to detect one CIN2+ 1.3 1.3 −2
CIN3+ 1.8 1.8 −2
ASC-US/LSIL
Number of referrals needed to detect one CIN2+ 3.0 4.7 57
CIN3+ 7.5 12.0 60
N.B. Triage algorithms for ASC-US/LSIL screens differ between the cytology-based and hrHPV-based programmes; in the hrHPV-based programme, all hrHPV-
positive, ASC-US/LSIL screens are directly referred, whereas in the cytology-based programme, ASC-US/LSIL screens were triaged for repeat cytology
after 6 months
*Total includes all positive hrHPV tests irrespective of the reflex cytology result (includes hrHPV-positive screens with reflex cytology of NILM, inadequate
or missing)
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included in our study has allowed us to make statistically
robust comparisons between indicators of the two pro-
grammes. Our study has some limitations. The follow-
up time included in our study was shorter for the
hrHPV-based programme than for the cytology-based
programme, as the hrHPV-based programme was imple-
mented more recently. We are unable to analyse character-
istics of non-attenders to the programme, as characteristics
of these women are not captured by PALGA. We are also
unable to differentiate loss to follow-up after referral for
colposcopy from cases where women attended colposcopy,
but no cytology or histological diagnostic test was
performed. This information is unavailable for both
the hrHPV-based programme and the cytology-based
programme. As such, we cannot investigate whether
adherence to referral advice has changed over time.
Furthermore, compliance to referral, used to differen-
tiate cytology only and no follow-up with cytology or
histology in Table 1, may have been underestimated
for hrHPV screening due to the shorter follow-up
time for the hrHPV-based programme; however, with-
out data on colposcopies, the extent of this underesti-
mation is unknown. The identifier used in PALGA to
link records is non-unique (based on the first eight
letters of a woman’s surname and her date of birth).
This means that records from multiple women could
be linked to one identifier (called an administrative
fusion). It is unlikely that there is a difference in the
number of administrative fusions between the two pro-
grammes, and therefore, we expect that this has not influ-
enced our results. Finally, because the cytology-based
programme recommended observation of ASC-US/LSIL
results, while the hrHPV-based programme recommended
colposcopic referral for hrHPV-positive, ASC-US/LSIL
results, distinguishing the relative impact of the hrHPV
test itself versus the lower threshold for referral on both
unnecessary testing and CIN2+ detection is difficult.
Conclusions
This is the first time that results of nationwide implementa-
tion of hrHPV-based screening have been reported using
high-quality data with extended follow-up. Our results
show implementation of the hrHPV-based programme has
been successful. However, the lower participation rate in
the hrHPV-based programme needs to be investigated fur-
ther to ensure that the screening programme remains
effective and efficient. Detection of CIN2+ lesions was
higher in the hrHPV-based programme at the cost of more
unnecessary referrals. Careful consideration needs to be
given to potentially changing triage of hrHPV-positive
screens to reduce unnecessary referrals. Ongoing monitor-
ing of the hrHPV-based programme is essential to ensure
that a reasonable balance of benefits and harms continues
to be achieved.
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